D3321
Dipeptidyl Peptidase VII human
recombinant, expressed in Sf9 cells
Synonym(s):
DPP7, Quiescent cell proline dipeptidase
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Enzyme Commission number:
3.4.14.-
UNSPSC Code:
12352204
NACRES:
NA.54
Recommended Products
recombinant
expressed in Sf9 cells
Quality Level
form
solution
specific activity
≥1,500 units/μg protein
≥1500 units/μg protein
mol wt
89.1 kDa
relevant disease(s)
diabetes; cardiovascular diseases
shipped in
dry ice
storage temp.
−70°C
Application
Dipeptidyl Peptidase VII (DPP7), also known as DPP2 or quiescent cell proline dipeptidase, is a post-proline cleaving aminopeptidase that is expressed in quiescent lymphocytes . DPP7 is used to study the regulation of cell quiescence . Like DPP4, DPP7 may be useful in diabetes and vascular disease research .
Biochem/physiol Actions
DPP7 is essential for maintaining lymphocytes and fibroblasts in G(0). The inhibition of DPP7 results in apoptosis, which is mediated by the induction of c-Myc and p53 . DPP7 has strong sequence homology with prolylcarboxypeptidase and is active at both acidic and neutral pH.
Physical properties
Contains amino acids 29 to end with a C-terminal His tag, MW=89.1 kDa
Unit Definition
One unit will hydrolyze 1.0 picomole of Ala-Pro-AMC per minute at pH 7.4 at 25 deg °C
Physical form
Supplied as a solution in 40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 220 mM imidazole, and 20% glycerol.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Dam. 1 - Repr. 1B - Skin Corr. 1C
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 2
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Dolan Sondhi et al.
Human gene therapy methods, 23(5), 324-335 (2012-11-08)
Late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal, lysosomal storage disorder caused by mutations in the CLN2 gene, results in a deficiency of tripeptidyl-peptidase I (TPP-I) activity in neurons. Our prior studies showed that delivery of the human CLN2 cDNA
Wengen Wu et al.
Bioorganic & medicinal chemistry letters, 22(17), 5536-5540 (2012-08-03)
The boroProline-based dipeptidyl boronic acids were among the first DPP-IV inhibitors identified, and remain the most potent known. We introduced various substitutions at the 4-position of the boroProline ring regioselectively and stereoselectively, and incorporated these aminoboronic acids into a series
Lin Zhu et al.
The Journal of general and applied microbiology, 58(3), 199-209 (2012-08-11)
Proteolytic degradation is one of the serious bottlenecks limiting the yields of heterologous protein production by Aspergillus oryzae. In this study, we selected a tripeptidyl peptidase gene AosedD (AO090166000084) as a candidate potentially degrading the heterologous protein, and performed localization
Mahesh Kamate et al.
Neurology India, 60(3), 316-320 (2012-07-25)
Neuronal ceroid lipofuscinosis is a group of progressive neurodegenerative disorders characterized by accumulation of ceroid lipopigment in lysosomes in neurons and other cell types. This study is a retrospective review of charts of patients with a diagnosis of infantile and
Katrin Witzel et al.
Neuropharmacology, 63(8), 1389-1403 (2012-09-12)
We examined the effects of the sulfonylurea compound NS5806 on neuronal A-type channel function. Using whole-cell patch-clamp we studied the effects of NS5806 on the somatodendritic A-type current (I(SA)) in cultured hippocampal neurons and the currents mediated by Kv4.2 channels
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service